Search research articles
Contact Us
Filters
Showing results (151-160 of 202) with videos related to
Page
of 21
Sort By:
British Journal of Cancer
|
July 26, 2012
Expression of oestrogen receptor β and prognosis of colorectal cancer
A Rudolph, C Toth, M Hoffmeister, et al.
Journal of Health Care for the Poor and Underserved
|
February 17, 2025
Psychiatric Emergency Service Use Trends: Adults Experiencing Homelessness in Massachusetts from 2005-2020
Kaila A Rudolph, Corinne A Beaugard, Cindy Xu, et al.
Pediatric Transplantation
|
February 23, 2022
Long-term outcomes of intestinal transplantation from donors aged under 1 year
Yu-Tang Chang, Kyle Soltys, Ajai Khanna, et al.
Journal of Medical Genetics
|
July 13, 2002
Linkage stratification and mutation analysis at the Parkin locus identifies mutation positive Parkinson's disease families
W C Nichols, N Pankratz, S K Uniacke, et al.
Neurology
|
September 1, 1994
The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group
K Kieburtz, M McDermott, P Como, et al.
The Journal of Urology
|
March 1, 1985
A, B and H antigens in normal urothelium: an immunohistochemical study using monoclonal antibodies with the avidin-biotin complex technique
G M Seal, R G Rowland, J V Thomalla, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 18, 2003
Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor
Pascal Bonaventure, Diane Nepomuceno, Curt Mazur, et al.
Oncogene
|
June 11, 1999
The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors
H C Crawford, B M Fingleton, L A Rudolph-Owen, et al.
Journal of Biological Response Modifiers
|
April 1, 1989
Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases
F Paolozzi, K Zamkoff, M Doyle, et al.
Journal of the National Cancer Institute
|
January 16, 1991
Hemorrhagic gastritis as a new dose-limiting toxicity of recombinant tumor necrosis factor
R L Krigel, K A Padavic-Shaller, A A Rudolph, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 202) with videos related to
Sort By:
Page
of 21
British Journal of Cancer
|
July 26, 2012
Expression of oestrogen receptor β and prognosis of colorectal cancer
A Rudolph, C Toth, M Hoffmeister, et al.
Journal of Health Care for the Poor and Underserved
|
February 17, 2025
Psychiatric Emergency Service Use Trends: Adults Experiencing Homelessness in Massachusetts from 2005-2020
Kaila A Rudolph, Corinne A Beaugard, Cindy Xu, et al.
Pediatric Transplantation
|
February 23, 2022
Long-term outcomes of intestinal transplantation from donors aged under 1 year
Yu-Tang Chang, Kyle Soltys, Ajai Khanna, et al.
Journal of Medical Genetics
|
July 13, 2002
Linkage stratification and mutation analysis at the Parkin locus identifies mutation positive Parkinson's disease families
W C Nichols, N Pankratz, S K Uniacke, et al.
Neurology
|
September 1, 1994
The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group
K Kieburtz, M McDermott, P Como, et al.
The Journal of Urology
|
March 1, 1985
A, B and H antigens in normal urothelium: an immunohistochemical study using monoclonal antibodies with the avidin-biotin complex technique
G M Seal, R G Rowland, J V Thomalla, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 18, 2003
Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor
Pascal Bonaventure, Diane Nepomuceno, Curt Mazur, et al.
Oncogene
|
June 11, 1999
The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors
H C Crawford, B M Fingleton, L A Rudolph-Owen, et al.
Journal of Biological Response Modifiers
|
April 1, 1989
Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases
F Paolozzi, K Zamkoff, M Doyle, et al.
Journal of the National Cancer Institute
|
January 16, 1991
Hemorrhagic gastritis as a new dose-limiting toxicity of recombinant tumor necrosis factor
R L Krigel, K A Padavic-Shaller, A A Rudolph, et al.
Page
of 21